Influenza viruses with mutant PB2 gene segment as live attenuated vaccines

A vaccine comprising an effective amount of a biologically contained influenza A virus comprising:

• 8 different viral segments including a PA viral segment, a PB1 viral segment, a mutant PB2 viral segment, a HA viral segment, a NA viral segment, a NP viral segment, a M (M1 and M2) viral segment, and a NS (NS1 and NS2) viral segment, wherein the mutant PB2 viral segment includes 5′ and 3′ incorporation sequences including 3′ or 5′ coding and non-coding incorporation sequences flanking a heterologous nucleotide sequence comprising a therapeutic or prophylactic gene and does not include contiguous sequences corresponding to sequences encoding a functional PB2, and wherein the HA viral segment encodes one of subtypes H1 to H16.